- Home
- BRBR vs XNCR Comparison
BRBR vs XNCR Comparison
Compare BRBR & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BRBR | XNCR |
|---|---|---|
| Founded | 2019 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | 2019 | 2013 |
Fundamental Metrics
Financial Performance| Metric | BRBR | XNCR |
|---|---|---|
| Price | $12.48 | $15.85 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 9 |
| Target Price | ★ $36.63 | $22.33 |
| AVG Volume (30 Days) | ★ 6.7M | 961.6K |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 65.36 |
| EPS | ★ 0.65 | N/A |
| Revenue | ★ $2,316,600,000.00 | $125,576,000.00 |
| Revenue This Year | $6.28 | N/A |
| Revenue Next Year | $5.81 | $4.80 |
| P/E Ratio | $18.69 | ★ N/A |
| Revenue Growth | ★ 16.05 | 13.65 |
| 52 Week Low | $7.82 | $6.92 |
| 52 Week High | $59.10 | $18.69 |
Technical Indicators
Market Signals| Indicator | BRBR | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 56.36 | 65.14 |
| Support Level | $9.22 | $15.69 |
| Resistance Level | $18.96 | $16.81 |
| Average True Range (ATR) | 0.92 | 0.94 |
| MACD | 0.14 | 0.11 |
| Stochastic Oscillator | 61.87 | 72.26 |
Price Performance
Historical ComparisonAbout BRBR BellRing Brands Inc.
BellRing Brands Inc is a United States-based company engaged in providing nutrition-related products. Its brands, Premier Protein, Dymatize, and PowerBar provides various products including ready-to-drink protein shakes, powders and nutrition bars. The company's products are distributed through a diverse network of channel including club, food, drug and mass, eCommerce, convenience and specialty.
About XNCR Xencor Inc.
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.